N/A N=15 Villency-Proof of Action: Foot Device, Balance and Sway, Kinematics of Walking
Balance
Primary: Center of Mass Displacement (Sway) During Standing — .62 centimeters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=14,099 Email Campaign to Increase Uptake of myGeisinger
Telehealth · Health Behavior
Primary: Email Opened: Control vs. Less-is-better vs. Social Proof vs. Endowment — 558; 1528; 375; 488 Participants — p=0.0248
N/A N=25 Objective Vision Evaluation of Two Cosmetic Contact Lenses
Visual Acuity
Primary: Distance Binocular Visual Acuity (logMAR) — -0.15; -0.18; 0.00; -0.04 logMAR
N/A N=55 CompaRison of Paresthesia Mapping to anatomIc Midline-based burSt Programming Strategies
Chronic Pain
Primary: Visual Analog Scale (VAS) for Back Pain at SCS Trial — 32; 30.5 units on a scale
Phase 1 N=34 Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
Dry Eye
Primary: Presence of Adverse Events (AEs) — 7; 8 Participants — p=0.409
Phase 2 N=180 Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
Rectal Cancer
Primary: Number of Patients Achieving Pathologic Complete Response (pCR). — 25; 9; 90; 56 Participants
Phase 3 N=36 The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
Antibody-mediated Rejection · Hyperacute Rejection of Cardiac Transplant · Left Ventricular Dysfunction
Primary: Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction — 4 Participants
N/A N=19 Heart at Work Study
Occupational Diseases · Cardiovascular Diseases · Cardiovascular Risk Factor
Primary: 24-hour Heart Rate — 83.8; 78.5 beats per minute
Phase 1 N=40 DPP4 Inhibition & Beta Cell Function
Healthy
Primary: Arginine-stimulated Insulin Secretion With and Without GLP-1 Blockade — 320.1; 243.4; 280; 251.2 pmol/L — p=< 0.05
N/A N=5,012 Timely Nudge About Lab Results to Increase myGeisinger Uptake
Telehealth · Health Behavior
Primary: Enrollment - Timely Email (Combined Email Arms) vs. no Intervention — 65; 361 Participants — p=<0.001
N/A N=27 Vagus Nerve Stimulation: Treatment for Gulf Veterans With Gulf War Illness
Pain · Migraine
Primary: Visual Analog Scale (VAS) to Assess Change of Widespread Pain — 4.70; 5.40; 5.43; 3.56 Units on a scale — p=0.47
N/A N=401 Responsible Fatherhood Opportunities for Reentry & Mobility
Healthy
Primary: Parental Role Satisfaction — 11.9; 11.4 units on a scale — p=0.29
Phase 1 N=191 Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Solid Tumor
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 59; 20; 21; 21 Participants
N/A N=65,406 Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Pulmonary Disease, Chronic Obstructive
Primary: Occurrence of First Hospitalisation or Hospital Outpatient Clinic Visit for Atrial Fibrillation or Flutter (AF) — 246; 725 Events
Phase 2 N=67 Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
Primary Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I — 25.97; 26.25; 25.90; 26.44 mmHg — p=0.028